Pulmocide Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: London United Kingdom (2007)

Organization Overview

First Clinical Trial
2017
NCT03236233
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Pulmocide Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

pc945 (6 trials)

Drugs in Phase 2 Trials (1)

tarenflurbil (2 trials)

Drugs in Phase 1 Trials (1)

pc786 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 2)

Asthma (Phase 2)

Bronchiectasis (Phase 2)

Candidiasis (Phase 2)

Communicable Diseases (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Infections (Phase 2)

Respiration Disorders (Phase 2)

Respiratory Syncytial Virus Infections (Phase 2)

Respiratory Tract Diseases (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 3